HR and breast cancer: Recently, the analysis of blood samples from 106 patients with HR+/HER2− metastatic BC treated with palbociclib in combination with fulvestrant as the first-line metastatic therapy showed that the appearance of KRAS mutations was associated with palbociclib resistance acquisition within 6 months [204].